Genelux Corp. (GNLX)
2.56
+0.04
(+1.59%)
USD |
NASDAQ |
Oct 02, 16:00
2.56
0.00 (0.00%)
After-Hours: 20:00
Genelux Net Income (Quarterly) : -9.471M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.471M |
| March 31, 2026 | -8.928M |
| December 31, 2025 | -9.247M |
| September 30, 2025 | -7.95M |
| June 30, 2025 | -7.456M |
| March 31, 2025 | -7.492M |
| December 31, 2024 | -8.976M |
| September 30, 2024 | -6.467M |
| June 30, 2024 | -6.576M |
| March 31, 2024 | -7.85M |
| December 31, 2023 | -6.767M |
| September 30, 2023 | -5.345M |
| Date | Value |
|---|---|
| June 30, 2023 | -5.821M |
| March 31, 2023 | -10.36M |
| December 31, 2022 | -3.495M |
| September 30, 2022 | 4.909M |
| June 30, 2022 | -2.82M |
| March 31, 2022 | -3.801M |
| December 31, 2021 | -3.74M |
| September 30, 2021 | -2.944M |
| June 30, 2021 | -6.695M |
| March 31, 2021 | -2.999M |
| March 31, 2020 | -3.772M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arcutis Biotherapeutics, Inc. | 15.01M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.471M |
| EPS Diluted (Quarterly) | -0.2107 |
| Enterprise Value | 99.22M |
| Earnings Yield | -33.90% |
| Normalized Earnings Yield | -33.90 |